Masimo Co. (NASDAQ:MASI) Position Reduced by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in Masimo Co. (NASDAQ:MASI) by 16.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 461,860 shares of the medical equipment provider’s stock after selling 90,700 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.89% of Masimo worth $39,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Comerica Bank boosted its position in shares of Masimo by 4.8% during the third quarter. Comerica Bank now owns 37,054 shares of the medical equipment provider’s stock worth $3,218,000 after acquiring an additional 1,708 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Masimo by 6.4% in the third quarter. Bank of New York Mellon Corp now owns 1,074,648 shares of the medical equipment provider’s stock valued at $93,021,000 after acquiring an additional 64,882 shares during the period. DekaBank Deutsche Girozentrale raised its stake in shares of Masimo by 78.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock valued at $182,000 after acquiring an additional 925 shares during the period. Rhumbline Advisers raised its stake in shares of Masimo by 18.7% in the third quarter. Rhumbline Advisers now owns 107,530 shares of the medical equipment provider’s stock valued at $9,308,000 after acquiring an additional 16,953 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Masimo by 49.9% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 97,918 shares of the medical equipment provider’s stock valued at $8,476,000 after acquiring an additional 32,575 shares during the period. Institutional investors and hedge funds own 83.74% of the company’s stock.

In other Masimo news, Director Steven Barker sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total transaction of $900,000.00. Following the transaction, the director now owns 73,249 shares of the company’s stock, valued at approximately $6,592,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Yongsam Lee sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $89.89, for a total transaction of $449,450.00. Following the completion of the sale, the executive vice president now owns 74,000 shares in the company, valued at $6,651,860. The disclosure for this sale can be found here. Insiders have sold a total of 53,074 shares of company stock worth $4,737,245 in the last three months. Insiders own 13.10% of the company’s stock.

Several brokerages have recently weighed in on MASI. BTIG Research raised shares of Masimo from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Monday, August 14th. BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $108.00 price target on shares of Masimo in a research note on Friday, November 3rd. Finally, Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research note on Thursday, November 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $97.17.

Masimo Co. (NASDAQ MASI) traded down $1.00 during midday trading on Wednesday, reaching $87.11. 269,524 shares of the company’s stock were exchanged, compared to its average volume of 611,259. The stock has a market cap of $4,571.35, a P/E ratio of 33.90, a price-to-earnings-growth ratio of 2.98 and a beta of 0.72. Masimo Co. has a 1-year low of $62.17 and a 1-year high of $104.71.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.17. The business had revenue of $193.69 million for the quarter, compared to the consensus estimate of $189.01 million. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 EPS. analysts expect that Masimo Co. will post 2.95 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/12/07/masimo-corporation-masi-stake-lessened-by-russell-investments-group-ltd.html.

About Masimo

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply